Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. We have built a broad toolkit across multiple technology platforms, including a diverse range of potentially first-in-class therapeutic approaches. This includes mRNA vaccines, cell and gene therapies, targeted antibodies, small molecule immunomodulators, Ribologicals, and next-generation immunomodulators. Our approach has created a robust and diversified product pipeline across infectious disease and oncology, including our first commercial product, COMIRNATY, our COVID-19 vaccine. COMIRNATY is the first ever approved mRNA drug product. Our clinical pipeline includes more than 25 product candidates in oncology and infectious diseases, including five randomized Phase 2 clinical trials in oncology. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. We believe we are well-positioned to develop and commercialize the next generation of immunotherapies with the potential to transform treatment paradigms for many severe diseases.
Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with the European Commission
Changes in the Supervisory Board of BioNTech SE and Voting Results from the Annual General Meeting 2023
BioNTech Announces First Quarter 2023 Financial Results and Corporate Update
BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
Data Provided by Refinitiv. Minimum 15 minutes delayed.